Literature DB >> 11755367

First dual NK(1) antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants.

Thomas Ryckmans1, Laurent Balançon, Olivier Berton, Christophe Genicot, Yves Lamberty, Benedicte Lallemand, Patrick Pasau, Nathalie Pirlot, Luc Quéré, Patrice Talaga.   

Abstract

Compounds combining NK(1) antagonism and serotonin reuptake inhibition are described, and potentially represent a new generation of antidepressants. Compound 24 displays good affinities for both the NK(1) receptor and the serotonin reuptake site (32 and 25 nM, respectively).

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11755367     DOI： 10.1016/s0960-894x(01)00727-2

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  5 in total

1.  Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors.

Authors:  Shayma El-Atawneh; Amiram Goldblum
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

Review 2.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

Review 3.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 4.  Chimeric Structures in Mental Illnesses-"Magic" Molecules Specified for Complex Disorders.

Authors:  Patrycja Kleczkowska
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

5.  Molecular Neurobiology and Promising New Treatment in Depression.

Authors:  Sang Won Jeon; Yong-Ku Kim
Journal:  Int J Mol Sci       Date:  2016-03-15       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.